Author:
Wei Lianhui,Tian Ye,Chen Xiao,Guo Xiaojing,Chen Chenxin,Zheng Yi,Xu Jinfang,Ye Xiaofei
Funder
the China Natural Science Foundation
the Leading Talents of Public Health in Shanghai
the Excellent Young Scholars of public health in Shanghai
the Construction Plan of key disciplines of Public Health system in Shanghai
Military Key Discipline Construction Project
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference30 articles.
1. Thrombosis and Hemostasis Group, Hematology Society of Chinese Medical Association; Hemophilia Treatment Center Collaborative Network of China. [Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)]. Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):364 – 70.
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
3. Fischer K, Lewandowski D, Marijke van den Berg H, et al. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia. 2012;18(3):e241-6.
4. Yoneyama K, Schmitt C, Kotani N, et al. Pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase iii dose selection for emicizumab in hemophilia A. Clin Pharmacokinet. 2018;57(9):1123–34.
5. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463–8.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献